Stock Analysis
- Sweden
- /
- Entertainment
- /
- NGM:VAXXA
Vaxxa First Quarter 2024 Earnings: EPS: kr0.012 (vs kr1.00 loss in 1Q 2023)
Vaxxa (NGM:VAXXA) First Quarter 2024 Results
Key Financial Results
- Revenue: kr21.1m (up 245% from 1Q 2023).
- Net income: kr312.0k (up from kr2.65m loss in 1Q 2023).
- Profit margin: 1.5% (up from net loss in 1Q 2023). The move to profitability was driven by higher revenue.
- EPS: kr0.012 (up from kr1.00 loss in 1Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Vaxxa shares are up 14% from a week ago.
Risk Analysis
We don't want to rain on the parade too much, but we did also find 5 warning signs for Vaxxa that you need to be mindful of.
Valuation is complex, but we're helping make it simple.
Find out whether Vaxxa is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Simply Wall St
About NGM:VAXXA
Vaxxa
Vaxxa AB operates an auction platform, vaxxa.se, which offers private individuals and companies to sell and buy used objects in vehicles, machinery, and construction industry.
Adequate balance sheet and slightly overvalued.